Abstract
Objective: The case aims to show anti-proteinuric effect of Chinese herbal medicines (CHM) in a patient with heavy proteinuric non-IgA mesangial proliferative glomerulonephritis (MsPGN). Subject: A 16-year-old boy was found edema in the lower limbs and a great quantity of urine protein for 4-months and diagnosed as non-IgA MsPGN via renal biopsy later, but there was no amelioration after receiving a shortdated comprehensive treatment including full amount of prednisone. Then he visited Prof. Ming Wan for traditional Chinese medicine (TCM) therapy. Interventions and outcome: This patient was treated with the integrated treatment, mainly including empirical Chinese herbal formulas (500 mL/day for 3-months), multi-glycoside of Tripterygium wilfordii Hook.f. (GTW) (90 mg/day for 3-months) and Losartan (50 mg/day for 3-months). His heavy proteinuria and clinical conditions were significantly improved after continuous treatment for 3-months and basically stable for nearly 3-years during the follow-up. Conclusions: Based on a variety of conventional drugs in clinic, the combined treatment of empirical Chinese herbal formulas and GTW was significantly effective in reducing massive proteinuria in non-IgA MsPGN patients, which is different from hormonotherapy.
Keywords: Case report, Chinese herbal medicines, multi-glycoside of Tripterygium wilfordii Hook.f. (GTW), Non-IgA mesangial proliferative glomerulonephritis, proteinuria.
Current Traditional Medicine
Title:A Case of Heavy Proteinuric Non-IgA Mesangial Proliferative Glomerulonephritis Ameliorated by Chinese Herbal Medicines
Volume: 1 Issue: 3
Author(s): Yan-ru Huang, Thomas Heaton, Yi-gang Wan, Zhi-min Mao and Jing-jing Yang
Affiliation:
Keywords: Case report, Chinese herbal medicines, multi-glycoside of Tripterygium wilfordii Hook.f. (GTW), Non-IgA mesangial proliferative glomerulonephritis, proteinuria.
Abstract: Objective: The case aims to show anti-proteinuric effect of Chinese herbal medicines (CHM) in a patient with heavy proteinuric non-IgA mesangial proliferative glomerulonephritis (MsPGN). Subject: A 16-year-old boy was found edema in the lower limbs and a great quantity of urine protein for 4-months and diagnosed as non-IgA MsPGN via renal biopsy later, but there was no amelioration after receiving a shortdated comprehensive treatment including full amount of prednisone. Then he visited Prof. Ming Wan for traditional Chinese medicine (TCM) therapy. Interventions and outcome: This patient was treated with the integrated treatment, mainly including empirical Chinese herbal formulas (500 mL/day for 3-months), multi-glycoside of Tripterygium wilfordii Hook.f. (GTW) (90 mg/day for 3-months) and Losartan (50 mg/day for 3-months). His heavy proteinuria and clinical conditions were significantly improved after continuous treatment for 3-months and basically stable for nearly 3-years during the follow-up. Conclusions: Based on a variety of conventional drugs in clinic, the combined treatment of empirical Chinese herbal formulas and GTW was significantly effective in reducing massive proteinuria in non-IgA MsPGN patients, which is different from hormonotherapy.
Export Options
About this article
Cite this article as:
Huang Yan-ru, Heaton Thomas, Wan Yi-gang, Mao Zhi-min and Yang Jing-jing, A Case of Heavy Proteinuric Non-IgA Mesangial Proliferative Glomerulonephritis Ameliorated by Chinese Herbal Medicines, Current Traditional Medicine 2015; 1 (3) . https://dx.doi.org/10.2174/221508380103151231142116
DOI https://dx.doi.org/10.2174/221508380103151231142116 |
Print ISSN 2215-0838 |
Publisher Name Bentham Science Publisher |
Online ISSN 2215-0846 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Antioxidant Capacity, Phytochemical Analysis and Identification of Active Compounds in Anchomanes difformis
The Natural Products Journal Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential
Current Neuropharmacology A Prevention of Pre-eclampsia with the Use of Acetylsalicylic Acid and Low-molecular Weight Heparin – Molecular Mechanisms
Current Pharmaceutical Biotechnology Leptin and the Regulation of Renal Sodium Handling and Renal Na+- Transporting ATPases: Role in the Pathogenesis of Arterial Hypertension
Current Cardiology Reviews Novel Therapeutic Approaches and Targets for the Treatment of Cardiovascular and Immunological Diseases
Current Pharmaceutical Biotechnology Calcium Ion – The Key Player in Cerebral Ischemia
Current Medicinal Chemistry Editorial(Thematic Issue: Hypertension and Diabetes – Update in 2013)
Current Hypertension Reviews Sustained Release of Diltiazem Hydrochloride from Chitosan Microcapsules
Current Drug Delivery Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Unfolded Protein Response as a Therapeutic Target in Cardiovascular Disease
Current Topics in Medicinal Chemistry Cardiac Chamber Volumetric Assessment Using 3D Ultrasound - A Review
Current Pharmaceutical Design Comparative Study of the Derivative and Partial Least Squares Methods Applied to the Spectrophotometric Simultaneous Determination of Atorvastatin and Amlodipine from their Combined Drug Products
Current Pharmaceutical Analysis Clinical Approach for the Treatment of Obesity-associated Diseases
Current Pharmaceutical Design Obesity in the Cardiovascular Continuum
Current Clinical Pharmacology Inflammation: A Link Between Hypertension and Atherosclerosis
Current Hypertension Reviews Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Fatty Acids and Obesity
Current Pharmaceutical Design Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Current Vascular Pharmacology